ADC license agreements have now generated over $65 million for Seattle Genetics.
Daiichi Sankyo obtained a license to Seattle Genetics’ antibody-drug conjugate (ADC) platform for use in solid tumors for $4 million upfront. Under the exclusive, worldwide agreement, Seattle Genetics will also receive progress-dependent milestone payments and mid-single digit royalties on worldwide net sales of resulting ADC products.
Daiichi Sankyo will leverage the technology to target a single antigen found on multiple types of solid tumors. The company is responsible for research, product development, manufacturing, and commercialization of all ADC products under the collaboration. Seattle Genetics will receive material supply and annual maintenance fees as well as research support payments for assistance provided.
ADCs utilize the targeting ability of mAbs to deliver potent, cell-killing payloads to specific cells, according to Seattle Genetics. To date, the firm has generated more than $65 million through ADC technology license agreements with numerous companies including Genentech, Bayer, CuraGen, Progenics, and AstraZeneca.